Guggenheim raised the firm’s price target on Vaxcyte to $130 from $101 and keeps a Buy rating on the shares. Top-line Phase 2 data for VAX-31 data reflect a “best case scenario,” confirming best-in-class immunogenicity across the broadest coverage and “securing VAX-31’s leadership position,” the analyst tells investors. VAX-31 is poised to be first-in-class and best-in-class in the $8B-plus pneumococcal vaccines market, the firm contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte price target raised to $140 from $101 at BofA
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte announces $1B common stock and warrants offering
- Vaxcyte price target raised to $153 at Leerink after VAX-31 ‘home run’
- Needham ups Vaxcyte target to $140 after ‘best-case scenario’ data